Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants - Full Text View

Sponsored by:	University of Cologne
Information provided by:	University of Cologne
ClinicalTrials.gov Identifier:	NCT00249951

Purpose

Preterm infants are at risk to develop nephrocalcinosis. Incidence numbers vary according to birth weight and gestation age. Very low birth weight infants have the highest risk index, with ~ 7-10 % of preterm infants developing nephrocalcinosis in the patient population. We, the researchers at the University of Cologne, and others found significantly decreased urinary citrate excretion (hypocitraturia) to be one of the main risk factors. Hence, we hypothesized, that prophylactic treatment with oral alkaline citrate solution (Shol's solution) would help to 1) increase urinary citrate excretion and 2) help to decrease the incidence of nephrocalcinosis.

Condition	Intervention	Phase
Nephrocalcinosis	Drug: Alkaline citrate	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Drug Information available for: Citric acid Sodium Citrate

U.S. FDA Resources

Further study details as provided by University of Cologne:

Primary Outcome Measures:

Prevention of nephrocalcinosis

Secondary Outcome Measures:

Increase in urinary citrate excretion

Estimated Enrollment:	80
Study Start Date:	November 2005

Eligibility

Ages Eligible for Study:	up to 8 Weeks
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Preterm infants < 32 weeks gestation age and < 1500 g birth weight

Exclusion Criteria:

Cardial, renal or gastrointestinal malformations
Chronic renal failure
Therapy with vitamin B6
High dose treatment with furosemide or dexamethasone
Addison's disease
Severe metabolic alkalosis
Worse clinical condition of preterm infant, which makes oral feeding impossible
Participation in other studies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249951

Contacts

Contact: Bernd Hoppe, Prof. Dr.	01149 221 478 4391	bernd.hoppe@uk-koeln.de
Contact: Bodo B Beck, MD	01149 221 478 4391	bodobbeck@aol.com

Locations

Germany
Prof. Dr. Bernd Hoppe	Recruiting
Cologne, Germany, D-50924
Contact: Bernd Hoppe, Prof. Dr. 01149 221 478 4391 bernd.hoppe@uk-koeln.de
Principal Investigator: Bernd Hoppe, Prof. Dr.

Sponsors and Collaborators

University of Cologne

Investigators

Principal Investigator:

Bernd Hoppe, Prof. Dr.

University Children's Hospital Cologne, Kerpenerstr. 62, D-50924 Cologne, Germany

More Information

Publications:

Sikora P, Roth B, Kribs A, Michalk DV, Hesse A, Hoppe B. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney Int. 2003 Jun;63(6):2194-9.

Hoppe B, Duran I, Martin A, Kribs A, Benz-Bohm G, Michalk DV, Roth B. Nephrocalcinosis in preterm infants: a single center experience. Pediatr Nephrol. 2002 Apr;17(4):264-8.

Hoppe B, Roth B, Bauerfeld C, Langman CB. Oxalate, citrate, and sulfate concentration in human milk compared with formula preparations: influence on urinary anion excretion. J Pediatr Gastroenterol Nutr. 1998 Oct;27(4):383-6.

Hoppe B, Hesse A, Neuhaus T, Fanconi S, Forster I, Blau N, Leumann E. Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition. Arch Dis Child. 1993 Sep;69(3 Spec No):299-303.

Study ID Numbers:	FG03-157
Study First Received:	November 3, 2005
Last Updated:	November 14, 2005
ClinicalTrials.gov Identifier:	NCT00249951 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Cologne:

nephrocalcinosis
premature infants
hypocitraturia
alcaline citrate therapy
Nephrocalcinosis in premature infants

Study placed in the following topic categories:

Calcinosis
Metabolic Diseases
Urologic Diseases
Citric Acid

Citrate
Kidney Diseases
Metabolic Disorder
Nephrocalcinosis

Additional relevant MeSH terms:

Calcium Metabolism Disorders
Calcinosis
Metabolic Diseases

Urologic Diseases
Kidney Diseases
Nephrocalcinosis

ClinicalTrials.gov processed this record on July 06, 2009